- Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension2022 | First Faculty of Medicine
- Comment on The symposium report of Actelion company at ESC Congress 20132013 | First Faculty of Medicine
- Drug therapy of pulmonary arterial hypertension in 20142014 | First Faculty of Medicine
- Current status and perspectives of pharmacotherapy of pulmonary arterial hypertension2011 | First Faculty of Medicine
- Current pharmacotherapy for chronic pulmonary hypertension2011 | First Faculty of Medicine
- Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension2010 | First Faculty of Medicine
- Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic.2012 | First Faculty of Medicine
- Pulmonary arterial hypertension in systemic connective diseases +12008 | Faculty of Medicine in Hradec Králové
- Stenosis of the left main coronary artery due to compression by a dilated pulmonary artery2012 | Second Faculty of Medicine
- Eisenmenger syndrome and complications in children - case report2020 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport
- Effect of Macitentan on Hospitalizations: Results From the SERAPH IN Trial2015 | First Faculty of Medicine
- COVID-19 in disorders of pulmonary circulation2020 | First Faculty of Medicine
- New possibilities in the treatment of chronic thromboembolic pulmonary hypertension2005 | First Faculty of Medicine
- Development of interest of pulmonary hypertension in the Czech Republic2014 | First Faculty of Medicine
- Long-term experience with implantable treprostinil pumps in pulmonary arterial hypertension2020 | First Faculty of Medicine
- Unraveling the epigenetic landscape of pulmonary arterial hypertension: implications for personalized medicine development2023 | First Faculty of Medicine
- Chronic thromboembolic pulmonary hypertension: role of medical therapy2013 | First Faculty of Medicine
- Riociguat, an oral soluble guanylate cyclase stimulator, in the treatment of pulmonary hypertension2016 | First Faculty of Medicine
- Successful bosentan treatment of fingertip ulcer in a patient with mixed connective tissue disease2013 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN2015 | First Faculty of Medicine
- Predictors of survival in patients with pulmonary hypertension and acute right heart failure2020 | First Faculty of Medicine
- Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension2022 | First Faculty of Medicine, Faculty of Social Sciences
- RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors2017 | First Faculty of Medicine
- Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial2018 | First Faculty of Medicine
- Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension2021 | First Faculty of Medicine
- Application of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre2016 | Faculty of Medicine in Hradec Králové
- SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension2017 | First Faculty of Medicine
- Drug Induced Pulmonary Arterial Hypertension2018 | First Faculty of Medicine
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality2018 | First Faculty of Medicine